Jupiter Neurosciences (JUNS) said late Monday it has priced an initial public offering of about 2.8 million shares of common stock at $4 per share.
The shares are expected to begin trading Tuesday on the Nasdaq market under the symbol "JUNS." The offering is expected to close Wednesday.
The company said it expects to receive gross proceeds of $11 million and intends to use them to fund a phase 2 clinical trial of its drug candidate Jotrol in patients with Parkinson's Disease, among other things.